Preliminary results of a phase I/II clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients

Xiaosong Li; Mark F. Naylor; Robert E. Nordquist; T. Kent Teague; C. Anthony Howard; Cynthia Murray; Wei R. Chen

doi:10.1117/12.843260

24 February 2010 Preliminary results of a phase I/II clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients

Xiaosong Li, Mark F. Naylor, Robert E. Nordquist, T. Kent Teague, C. Anthony Howard, Cynthia Murray, Wei R. Chen

Author Affiliations +

Proceedings Volume 7565, Biophotonics and Immune Responses V; 756506 (2010) https://doi.org/10.1117/12.843260
Event: SPIE BiOS, 2010, San Francisco, California, United States

Abstract

In Situ Photoimmunotherapy (ISPI), a newly developed modality for cancer therapy, has been shown to be able to modulate the body's own immune response. This clinical trial was designed to evaluate the safety and therapeutic effect of ISPI, using imiquimod as its immunoadjuvant for metastatic melanoma patients. ISPI consisted of three main components applied directly to the cutaneous metastases: 1) local application of topical imiquimod; 2) injection of indocyanine green; and 3) an 805 nm laser for local irradiation. All patients completed at least one cycle of treatment. All the patients completed at least one cycle of treatments; one patient received 6 cycles. The most common adverse effects were rash, pruritus, pain, fatigue and anorexia. Fever, chills, vomiting and cellulitis were relative rare. No grade 4 toxicity was observed. Complete Response (CR) was observed in 6 patients. Median overall survival of the 11 evaluated patients was 12.2 months. Six of the eleven patients were still alive at the time of this report. Treatment of ISPI using imiquimod is safe and well tolerant. Our preliminary clinical results suggest that this new method can be a promising modality for metastatic melanoma.

Citation Download Citation

Xiaosong Li, Mark F. Naylor, Robert E. Nordquist, T. Kent Teague, C. Anthony Howard, Cynthia Murray, and Wei R. Chen "Preliminary results of a phase I/II clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients", Proc. SPIE 7565, Biophotonics and Immune Responses V, 756506 (24 February 2010); https://doi.org/10.1117/12.843260

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

;

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE